
## CLAIMS

**What is claimed is:**

**1.** A method for treating a subject suffering from a disease or condition mediated by a protein kinase selected from c-fms, c-kit, Flt3 or combinations thereof and/or macrophages or microglia, said method comprising administering to the subject an effective amount of a compound of Formula I',








Formula I'

or a pharmaceutically acceptable salt, a prodrug, a tautomer or an isomer thereof,

wherein:

Ar is selected from the group consisting of:

, , , , and ; wherein  indicates the point of attachment of Ar to $-CH_2-$ of Formula I and wherein  indicates the point of attachment of Ar to -NH- of Formula I';

$R^1$, $R^2$, $R^3$ and $R^4$ are each independently selected from the group consisting of –H, halogen, lower alkyl, halogen substituted lower alkyl, halogen substituted lower alkoxy, alkoxy substituted lower alkyl, cycloalkylamino, -CN, $-O-R^{40}$, $-S(O)_2-R^{41}$, $-S(O)_2-N(H)-R^{42}$, $-N(H)-R^{42}$, $-N(R^{42})_2$, and $-N(H)-S(O)_2-R^{43}$, provided that at least two of $R^1$, $R^2$, $R^3$ and $R^4$ are –H and one of $R^1$, $R^2$, $R^3$ and $R^4$ is other than hydrogen, wherein:

$R^{40}$ is lower alkyl, fluoro substituted lower alkyl, methoxy substituted lower alkyl, or cycloalkyl; and

$R^{41}$, $R^{42}$ and $R^{43}$ are lower alkyl;

$R^5$ is selected from the group consisting of -H, -F, -Cl, -Br, lower alkyl, halogen substituted alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, $-O-R^{10}$, $-C(O)-N(H)-R^{11}$, $-C(O)-O-R^{11}$,

$-S(O)_2-R^{12}$, $-S(O)_2-N(H)-R^{11}$, $-N(H)-C(O)-R^{12}$, and $-N(H)-S(O)_2-R^{12}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl;

$R^6$ is selected from the group consisting of H, halogen, lower alkyl, halogen substituted alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, $-O-R^{13}$, $-C(O)-N(H)-R^{14}$, $-C(O)-O-R^{14}$, $-S(O)_2-R^{15}$, $-S(O)_2-N(H)-R^{14}$, $-N(H)-C(O)-R^{15}$, and $-N(H)-S(O)_2-R^{15}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl;

$R^7$ is H, halogen or lower alkyl;

$R^8$ is H, halogen or lower alkoxy;

$R^9$ is H or halogen;

$R^{10}$ and $R^{13}$ are independently -H, lower alkyl, lower alkyl substituted with $-O-CH_3$, lower alkyl substituted with di-alklylamine, or lower alkyl substituted with heterocycloalkyl;

$R^{11}$ and $R^{14}$ are independently hydrogen or lower alkyl; and

$R^{12}$ and $R^{15}$ are each independently lower alkyl,

wherein the disease or condition is selected from stem cell ablation and myelopreparation for stem cell transplant, primary progressive multiple sclerosis, complex regional pain syndrome, reflex sympathetic dystrophy, muscular dystrophy, duchenne muscular dystrophy, causalgia, neuro-inflammation, neuroinflammatory disorders, benign forgetfulness, HIV, binswager type dementia, dementia with lewy bodie, prosencephaly, microencepahy, cerebral palsy, congenital hydrocephalus, abdominal dropsy, progressive supranuclear palsy, glaucoma, addiction disorders, dependencies, alcoholism, tremors, Wilson's disease, vascular dementias, multi infarct dementia, fronto temporal dementia, pseudo-dementia, bladder cancer, basal cell carcinoma, cholangiocarcinoma, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma , gastric cancer, glioma , hepatocellular carcinoma, Hodgkin lymphoma, laryngeal carcinoma , leukemia , liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, renal cancer, squamous cell carcinoma, t cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumors, malignant peripheral nerve sheath tumors (MPNST), cutaneous and plexiform neurofibromas, leiomyoadenomatoid tumor, fibroids, uterine fibroids, leiomyosarcoma, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, hurthle cell carcinoma, thyroid cancer, ascites, malignant ascites, mesothelioma, salivary gland tumors, mucoepidermoid carcinoma of the salivary gland, acinic cell carcinoma of the salivary gland, gastrointestinal stromal tumors (GIST), tumors that cause effusions in potential spaces of the body, pleural effusions, pericardial effusions, peritoneal effusions aka ascites, giant cell tumors (GCT), GCT of bone, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), TCGT of tendon sheath (TGCT-TS), other sarcomas, tumor angiogenesis, paracrine tumor growth or

tumors that express aberrantly or otherwise Fms, CSF1R, CSF1 or IL-34, or activating mutations or translocations of any of the foregoing.

**2.** The method of claims **1**, wherein:

i) $R^1$, $R^3$ and $R^4$ are H and $R^2$ is halogen; or

ii) $R^1$, $R^2$ and $R^3$ are -H and $R^4$ is halo substituted lower alkyl; or

iii) $R^1$ and $R^4$ are –H and $R^2$ is lower alkoxy; or

iv) $R^3$ is halogen; or

v) $R^2$ and $R^4$ are -H, $R^1$ is lower alkoxy and $R^3$ is halogen; or

vi) $R^1$ and $R^4$ are –H, $R^3$ is halogen and $R^2$ is lower alkoxy.

**3.** The method of claim **2**, wherein

i) $R^1$, $R^2$ and $R^3$ are -H and $R^4$ is $CF_3$; or

ii) $R^1$ and $R^4$ are –H and $R^2$ is $-OCH_3$; or

iii) $R^3$ is F; or

iv) $R^2$ and $R^4$ are -H, $R^1$ is $OCH_3$ and $R^3$ is F; or

v) $R^1$ and $R^4$ are –H, $R^3$ is F and $R^2$ is OCH3.

**4.** The method of any of claims **1-3**, wherein $R^5$ is -H, -F, -Cl, -Br, lower alkyl, fluoro substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, -O-$R^{10}$, -C(O)-N(H)-$R^{11}$, -C(O)-O-$R^{11}$, -$S(O)_2$-$R^{12}$, -$S(O)_2$-N(H)-$R^{11}$, -N(H)-C(O)-$R^{12}$, and -N(H)-$S(O)_2$-$R^{12}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl

**5.** The method of any of claims **1-3**, wherein $R^6$ is selected from the group consisting of H, halo, lower alkyl, fluoro substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, -O-$R^{13}$, -C(O)-N(H)-$R^{14}$, -C(O)-O-$R^{14}$, -$S(O)_2$-$R^{15}$, -$S(O)_2$-N(H)-$R^{14}$, -N(H)-C(O)-$R^{15}$, and -N(H)-$S(O)_2$-$R^{15}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl.

**6.** The method of claim **5**, wherein $R^6$ is halo, lower alkyl or fluoro substituted lower alkyl.

**7.** The method of any of claims **1-4**, wherein $R^7$ is H, halogen or lower alkyl.

**8.** The method of claim **7**, wherein $R^7$ is H, -F, -Cl, Br or $-CH_3$.

**9.** The method of any of claims **1-4**, wherein $R^8$ is H, halogen or lower alkoxy.

**10.** The method of claim **9**, wherein $R^8$ is H, -F, -Cl, Br or $-OCH_3$.

**11.** The method of claim **1-4**, wherein $R^9$ is H or halogen.

**12.** The method of claim **11**, wherein $R^9$ is -H or –Cl.

**13.** The method of claim **1**, wherein:

$R^1$, $R^3$ and $R^4$ are –H, and $R^2$ is -F, -Cl or -Br; or $R^1$, $R^2$ and $R^3$ are -H and $R^4$ is $-CF_3$; or $R^1$ and $R^4$ are -H, $R^2$ is $-O-CH_3$, and $R^3$ is -F; or $R^2$ and $R^4$ are -H, $R^1$ is $-O-CH_3$, and $R^3$ is -F;

$R^5$ is selected from the group consisting of -H, -F, -Cl, -Br, lower alkyl, fluoro substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, $-O-R^{10}$, $-C(O)-N(H)-R^{11}$, $-C(O)-O-R^{11}$, $-S(O)_2-R^{12}$, $-S(O)_2-N(H)-R^{11}$, $-N(H)-C(O)-R^{12}$, and $-N(H)-S(O)_2-R^{12}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl;

$R^6$ is selected from the group consisting of -H, -F, -Cl, -Br, lower alkyl, fluoro substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, pyrazolyl, -CN, $-O-R^{13}$, $-C(O)-N(H)-R^{14}$, $-C(O)-O-R^{14}$, $-S(O)_2-R^{15}$, $-S(O)_2-N(H)-R^{14}$, $-N(H)-C(O)-R^{15}$, and $-N(H)-S(O)_2-R^{15}$, wherein pyrazolyl is optionally substituted with lower alkyl or heterocycloalkyl;

$R^7$ is -H, -F, -Cl, or $-CH_3$;

$R^8$ is -H, -F, $-CH_3$, or $-O-CH_3$;


$R^9$ is -H or -Cl;

$R^{10}$ and $R^{13}$ are independently -H, lower alkyl, lower alkyl substituted with $-O-CH_3$, lower alkyl substituted with di-alklylamine, or lower alkyl substituted with heterocycloalkyl;

$R^{11}$ and $R^{14}$ are independently hydrogen or lower alkyl; and

$R^{12}$ and $R^{15}$ are each independently lower alkyl.

**14.** The method of claim **1**, wherein the compound has Formula II':




Formula II'

wherein:

$R^{16}$, $R^{17}$, $R^{18}$ and $R^{19}$ are each independently selected from the group consisting of H, halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl, alkoxy substituted lower alkyl, cycloalkylamino, -CN, $-O-R^{20}$, $-S(O)_2-R^{21}$, $-S(O)_2-N(H)-R^{22}$, $-N(H)-R^{22}$, $-N(R^{22})_2$, and $-N(H)-S(O)_2-R^{23}$, provided that at least two of $R^{16}$, $R^{17}$, $R^{18}$ and $R^{19}$ are -H;


$R^{20}$ is lower alkyl, fluoro substituted lower alkyl, methoxy substituted lower alkyl, or cycloalkyl;

$R^{21}$ is lower alkyl;

$R^{22}$ is lower alkyl; and


$R^{23}$ is lower alkyl.

**15**. The method of claim **14**, having Formula II:




Formula II.

**16**. The method of claim **14**, having Formula IIa:



Formula IIa.

**17**. The method of claim **1**, wherein the compound has Formula III':



Formula III'

wherein:

$R^{24}$, $R^{25}$, $R^{26}$ and $R^{27}$ are each independently selected from the group consisting of -H, halogen, lower alkyl, lower alkoxy, halo substituted lower alkyl, lower alkoxy, alkoxy substituted lower alkyl, cycloalkylamino, -CN, -O-$R^{28}$, -$S(O)_2$-$R^{29}$, -$S(O)_2$-N(H)-$R^{30}$, -N(H)-$R^{30}$, -$N(R^{30})_2$, and -N(H)-$S(O)_2$-$R^{31}$, provided that at least two of $R^{24}$, $R^{25}$, $R^{26}$ and $R^{27}$ are -H;


$R^{28}$ is lower alkyl, fluoro substituted lower alkyl, methoxy substituted lower alkyl, or cycloalkyl;

$R^{29}$ is lower alkyl;

$R^{30}$ is lower alkyl; and


$R^{31}$ is lower alkyl.

**18**. The method of claim **17**, wherein the compound has Formula III:



Formula III.

**19.** A method for treating a subject suffering from a disease or condition mediated a protein kinase selected from c-fms, c-kit, flt3 or combinations thereof and/or macrophages or microglia, said method comprising administering to the subject an effective amount of a compound of Formula IV:



IV


or a pharmaceutically acceptable salt, a prodrug, a tautomer or an isomer thereof,

wherein:

$L_4$ is $-CH_2-$, $-CH_2CH_2-$, $-CH(R^{40})-$, -C(O)- or -C(O)NH-;

$R^{81}$ is selected from the group consisting of hydrogen, $-OR^{41}$, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, $-NHR^{41}$, $-NR^{41}R^{41}$, $-OR^{41}$ and $-S(O)_2R^{41}$;

$R^{82}$ is selected from the group consisting of hydrogen, fluoro, $C_{1-3}$ alkyl, fluoro substituted $C_{2-3}$ alkyl, OH, $C_{1-3}$ alkoxy, and fluoro substituted $C_{1-3}$ alkoxy;

$R^{83}$ is heterocycloalkyl, heteroaryl, or  , in which  indicates the attachment point of $R^{83}$ to $L_4$ of Formula III, wherein heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, $-NHR^{41}$, $-NR^{41}R^{41}$, $-OR^{41}$ and $-S(O)_2R^{41}$;

$R^{92}$, $R^{93}$, $R^{94}$, $R^{95}$, and $R^{96}$ are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, $-NHS(O)_2R^{41}$, $-NHC(O)R^{41}$, $-NHR^{41}$, $-NR^{41}R^{41}$, $-OR^{41}$ and $-S(O)_2R^{41}$;

$R^{40}$ is selected from the group consisting of lower alkyl, and fluoro substituted lower alkyl;

$R^{41}$ at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as $R^{41}$ or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, $-NH_2$, -CN, $-NO_2$, $-S(O)_2NH_2$, $-C(O)NH_2$, $-OR^{42}$, $-SR^{42}$, $-NHR^{42}$, $-NR^{42}R^{42}$, $-NR^{39}C(O)R^{42}$, $-NR^{39}S(O)_2R^{42}$, $-S(O)_2R^{42}$, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; and

$R^{42}$ at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy; provided, however, that the compound is other than those set forth in Table 2,

wherein the disease or condition is selected from stem cell ablation and myelopreparation for stem cell transplant, primary progressive multiple sclerosis, complex regional pain syndrome, reflex sympathetic dystrophy, muscular dystrophy, duchenne muscular dystrophy, causalgia, neuro-inflammation, neuroinflammatory disorders, benign forgetfulness, HIV, binswager type dementia, dementia with lewy bodie, prosencephaly, microencepahy, cerebral palsy, congenital hydrocephalus, abdominal dropsy, progressive supranuclear palsy, glaucoma, addiction disorders, dependencies, alcoholism, tremors, Wilson's disease, vascular dementias, multi infarct dementia, fronto temporal dementia, pseudo-dementia,

bladder cancer, basal cell carcinoma, cholangiocarcinoma, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma , gastric cancer, glioma , hepatocellular carcinoma, Hodgkin lymphoma, laryngeal carcinoma , leukemia , liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, renal cancer, squamous cell carcinoma, t cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumors, malignant peripheral nerve sheath tumors (MPNST), cutaneous and plexiform neurofibromas, leiomyoadenomatoid tumor, fibroids, uterine fibroids, leiomyosarcoma, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, hurthle cell carcinoma, thyroid cancer, ascites, malignant ascites, mesothelioma, salivary gland tumors, mucoepidermoid carcinoma of the salivary gland, acinic cell carcinoma of the salivary gland, gastrointestinal stromal tumors (GIST), tumors that cause effusions in potential spaces of the body, pleural effusions, pericardial effusions, peritoneal effusions aka ascites, giant cell tumors (GCT), GCT of bone, pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), TCGT of tendon sheath (TGCT-TS), other sarcomas, tumor angiogenesis, paracrine tumor growth or tumors that express aberrantly or otherwise Fms, CSF1R, CSF1 or IL-34, or activating mutations or translocations of any of the foregoing.

**20**. The method of claim **19**, wherein:

$L_4$ is $-CH_2$ or -C(O)-;

$R^{81}$ is selected from the group consisting of hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy;

$R^{82}$ is hydrogen or fluoro;

$R^{83}$ is, nitrogen containing heteroaryl, wherein nitrogen containing heteroaryl is optionally substituted with one or two substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, $-NHR^{51}$, $-NR^{51}R^{51}$, $-OR^{51}$ and $-S(O)_2R^{51}$; and

$R^{51}$ at each occurrence is independently lower alkyl or cycloalkyl, wherein lower alkyl is optionally substituted with one or more fluoro.

**21**. A method for treating a subject suffering from a disease or condition as described herein, said method comprising administering to the subject a pharmaceutical composition comprising a compound of any of formulas (I), (I'), (II), (II'), (IIa), (III), (III') and (IV), or a compound set forth in any of Tables 1 and 3-10 and another therapeutic agent, wherein the other therapeutic agent is selected from the group consisting of:

i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan;

ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; an antimetabolite, including, but not limited to, azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate;

iii) an antibody therapy agent selected from alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, and 90 Y ibritumomab tiuxetan; a hormone or hormone antagonist, including, but not limited to, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene;

iv) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel;

v) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin;

vi) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine;

vii) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide;

viii) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan (also active metabolite SN-38 (7-ethyl-10-hydroxy-camptothecin)), rubitecan, topotecan, and 9-aminocamptothecin;

ix) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), vemurafenib, dabrafenib, selumetinib and vatalanib;

x) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin;

xi) a biological response modifier selected from imiquimod, interferon-α, and interleukin-2; and

xii) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389), ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, mTOR inhibitors (e.g. sirolimus, temsirolimus, everolimus, deforolimus), PI3K inhibitors (e.g. BEZ235, GDC-0941, XL147, XL765), Cdk4 inhibitors (e.g. PD-332991), Akt inhibitors, Hsp90 inhibitors (e.g. geldanamycin, radicicol, tanespimycin), farnesyltransferase inhibitors (e.g. tipifarnib) and Aromatase inhibitors (anastrozole letrozole exemestane);

xiii) a Mek inhibitor;

xiv) a tyrosine kinase inhibitor as described herein; and

xv) an EGFR inhibitor.

22. A method for inhibiting tumor associated macrophages, microglia cells, monocytes, osteoclasts or combinations thereof, said method comprising: contacting the cell with a compound of any of formulas (I), (I'), (II), (II'), (IIa), (III), (III') and (IV), or a compound set forth in any of Tables 1 and 3-10 or composition as described herein.

23. A method for inhibiting tumor associated macrophages, microglia cells, monocytes, osteoclasts or combinations thereof in a subject, said method comprising: administering to the subject an effective amount of a compound of any of formulas (I), (I'), (II), (II'), (IIa), (III), (III') and (IV), or a compound set forth in any of Tables 1 and 3-10 or a composition as described herein.

24. A method for treating a subject suffering from a disease or condition mediated by a protein kinase selected from c-fms, c-kit, flt3 or combinations thereof and/or macrophages or microglia, said method comprising administering to the subject an effective amount of a compound of Tables 1, 3 and 4-10 or a compound or composition as described herein.

## CLAIMS

1. An invention not claimed in any divisional application.